Phase 2 trial of silevertinib in 43 frontline NSCLC patients with EGFR non-classical mutations (NCMs) showed a median progression-free survival (mPFS) of 15.2 months. Median duration of response (DOR) has not yet been reached, with 53% of patients remaining on therapy. The study reported an 86% CNS objective response rate (ORR) and no new de novo brain metastases. Overall ORR and disease control rate (DCR) were 60% and 91%, respectively. Safety data indicates a 28% rate of treatment-related adverse events (TRAEs) greater than Grade 3 following dose reduction, supporting a 150 mg QD dose for future pivotal development.